Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508766 | 0.90 | NCF1 (0.54) | NCF1HRH3CYP2D6 | |
| SCHEMBL15045128 | 0.88 | NCF1 (0.52) | NCF1HRH3CYP2D6OPRM1OPRL1 | |
| SCHEMBL2689734 | 0.86 | NCF1 (0.41) | NCF1HRH3PHGDHMGLLSLC18A3 | |
| SCHEMBL3637358 | 0.82 | NCF1 (0.41) | NCF1HRH3DPP4 | |
| SCHEMBL13672013 | 0.81 | NCF1 (0.44) | NCF1CYP2D6DPP4HTR6MEN1 | |
| SCHEMBL4476349 | 0.81 | NCF1 (0.44) | NCF1CYP2D6DPP4HTR6MEN1 | |
| SCHEMBL6379437 | 0.80 | NCF1 (0.45) | NCF1HRH3 | |
| SCHEMBL15045109 | 0.80 | NCF1 (0.75) | NCF1HRH3 | |
| SCHEMBL29922552 | 0.79 | NCF1 (0.43) | NCF1CYP2D6DPP4MEN1KMT2A | |
| SCHEMBL20756700 | 0.78 | NCF1 (0.36) | NCF1PHGDHMGLLCYP2D6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212647-B1 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG A ST CO LTD (KR) | 2019-04-03 | — | — | EP | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-3212647-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068580-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | NCF1 1073/4885HRH3 3734/4885PHGDH 660/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | NCF1 662/4885HRH3 3417/4885PHGDH 1155/4885 |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | NCF1 2584/4885HRH3 872/4885PHGDH 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.